PARIS – Sanofi and GlaxoSmithKline’s potential COVID-19 vaccine triggered strong immune responses in all adult age groups in preliminary trials, boosting optimism the shot may join the fight against the pandemic this year.
After two doses of the vaccine candidate, participants showed neutralizing antibodies in line with those found in people who had recovered from the disease, according to results of the Phase 2 trial released Monday.
The drugmakers said they plan to begin late-stage trials and production in the coming weeks and hope to win regulatory approval for the vaccine before the end of 2021.
Regulators have already authorized a number of COVID-19 vaccines, though experts say more are needed as public health authorities around the